Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29771427 | 0.84 | L3MBTL1 (0.48) | L3MBTL1HTTPOLBALDH3A1NOD1 | |
| SCHEMBL29110516 | 0.84 | L3MBTL1 (0.48) | L3MBTL1HTTPOLBALDH3A1NOD1 | |
| SCHEMBL260617 | 0.83 | L3MBTL1 (0.55) | L3MBTL1HTR6HTTPOLBALDH3A1 | |
| SCHEMBL18419022 | 0.81 | TP53 (0.54) | L3MBTL1HTTKDM4EALDH1A1CYP3A4 | |
| SCHEMBL10228229 | 0.81 | L3MBTL1 (0.43) | L3MBTL1HTR6GRM1HTTPOLB | |
| SCHEMBL1356181 | 0.81 | L3MBTL1 (0.52) | L3MBTL1HTR6HTTPOLBALDH3A1 | |
| SCHEMBL14427677 | 0.81 | L3MBTL1 (0.52) | L3MBTL1HTR6HTTPOLBALDH3A1 | |
| SCHEMBL4075074 | 0.81 | L3MBTL1 (0.52) | L3MBTL1HTR6HTTPOLBALDH3A1 | |
| SCHEMBL30752005 | 0.81 | L3MBTL1 (0.52) | L3MBTL1HTR6HTTPOLBALDH3A1 | |
| SCHEMBL28622254 | 0.81 | L3MBTL1 (0.52) | L3MBTL1HTR6HTTPOLBALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605420-A | Synthesis method of olatinib maleate | 江苏慧聚药业股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-118598877-A | Ola maleate preparation method of tenib | 艾美科健（中国）生物医药有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-115038703-B | Preparation method of tofacitinib and intermediate product thereof | 阿尔第实业有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-114605420-B | Synthesis method of olatinib maleate | 江苏慧聚药业股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-114605420-B | Synthesis method of olatinib maleate | 江苏慧聚药业股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-3248980-B1 | JAK INHIBITOR | WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) | 2023-09-06 | — | — | EP | disclosed |
| US-20230219963-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 2023-07-13 | — | — | US | disclosed |
| CN-115038703-A | Preparation method of tofacitinib and intermediate product thereof | 阿尔第实业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-114605420-A | Synthesis method of olatinib maleate | 江苏慧聚药业股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114605420-A | Synthesis method of olatinib maleate | 江苏慧聚药业股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| EP-1891066-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-22 | — | — | EP | disclosed |
| EP-1891066-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-22 | — | — | EP | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| CN-101233138-A | Pyrrolo[2,3-d]pyrimidine derivatives, their intermediates and synthesis | PFIZER PROD INC (US) | 2008-07-30 | — | — | CN | disclosed |
| EP-1891066-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006124462-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | SRC, FYN, SYK | L3MBTL1 4367/4885HTR6 2727/4885GRM1 1932/4885 |
| US-20230219963-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | L3MBTL1 4224/4885HTR6 2156/4885GRM1 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.